<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Arthritis Res Ther</journal-id><journal-title>Arthritis Research &#x00026; Therapy</journal-title><issn pub-type="ppub">1478-6354</issn><issn pub-type="epub">1478-6362</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">ar2442</article-id><article-id pub-id-type="pmid">18573197</article-id><article-id pub-id-type="doi">10.1186/ar2442</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>The association between disease activity and NT-proBNP in 238 patients with rheumatoid arthritis: a 10-year longitudinal study</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>Provan</surname><given-names>Sella A</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>s-provan@diakonsyk.no</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Angel</surname><given-names>Kristin</given-names></name><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I3">3</xref><email>kristin.angel@medisin.uio.no</email></contrib><contrib id="A3" contrib-type="author"><name><surname>&#x000d8;deg&#x000e5;rd</surname><given-names>Sigrid</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>sigrid.odegard@diakonsyk.no</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Mowinckel</surname><given-names>Petter</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>petter.mowinckel@diakonsyk.no</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Atar</surname><given-names>Dan</given-names></name><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I3">3</xref><email>dan.atar@online.no</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Kvien</surname><given-names>Tore K</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>t.k.kvien@medisin.uio.no</email></contrib></contrib-group><aff id="I1"><label>1</label>Department of Rheumatology, Diakonhjemmet Hospital, Box 23 Vindern, N-0319 Oslo, Norway</aff><aff id="I2"><label>2</label>Faculty of Medicine, University of Oslo, Pb1018 0316 Oslo, Norway</aff><aff id="I3"><label>3</label>Aker University Hospital, Division of Cardiology, University of Oslo, Trondheimsveien 235, 0514 Oslo, Norway</aff><pub-date pub-type="ppub"><year>2008</year></pub-date><pub-date pub-type="epub"><day>23</day><month>6</month><year>2008</year></pub-date><volume>10</volume><issue>3</issue><fpage>R70</fpage><lpage>R70</lpage><ext-link ext-link-type="uri" xlink:href="http://arthritis-research.com/content/10/3/R70"/><history><date date-type="received"><day>29</day><month>1</month><year>2008</year></date><date date-type="rev-request"><day>13</day><month>2</month><year>2008</year></date><date date-type="rev-recd"><day>12</day><month>5</month><year>2008</year></date><date date-type="accepted"><day>23</day><month>6</month><year>2008</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2008 Provan et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2008</copyright-year><copyright-holder>Provan et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an open access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Provan A Sella s-provan@diakonsyk.no </dc:author><dc:title> The association between disease activity and NT-proBNP in 238 patients with rheumatoid arthritis: a 10-year longitudinal study </dc:title><dc:date>2008</dc:date><dcterms:bibliographicCitation>Arthritis Research &#x00026; Therapy 10(3): R70-. (2008)</dcterms:bibliographicCitation><dc:identifier type="sici">1478-6354(2008)10:3&#x0003c;R70&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1478-6354</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Introduction</title><p>Disease activity in patients with rheumatoid arthritis (RA) is associated with increased cardiovascular morbidity and mortality, of which N-terminal pro-brain natriuretic peptide (NT-proBNP) is a predictor. Our objective was to examine the cross-sectional and longitudinal associations between markers of inflammation, measures of RA disease activity, medication used in the treatment of RA, and NT-proBNP levels (dependent variable).</p></sec><sec sec-type="methods"><title>Methods</title><p>Two hundred thirty-eight patients with RA of less than 4 years in duration were followed longitudinally with three comprehensive assessments of clinical and radiographic data over a 10-year period. Serum samples were frozen and later batch-analyzed for NT-proBNP levels and other biomarkers. Bivariate, multivariate, and repeated analyses were performed.</p></sec><sec><title>Results</title><p>C-reactive protein (CRP) levels at baseline were cross-sectionally associated with NT-proBNP levels after adjustment for age and gender (<italic>r</italic><sup>2 </sup>adjusted = 0.23; <italic>P </italic>&#x0003c; 0.05). At the 10-year follow-up, risk factors for cardiovascular disease were recorded. Duration of RA and CRP levels were independently associated with NT-proBNP in the final model that was adjusted for gender, age, and creatinine levels (<italic>r</italic><sup>2 </sup>adjusted = 0.38; <italic>P </italic>&#x0003c; 0.001). In the longitudinal analyses, which adjusted for age, gender, and time of follow-up, we found that repeated measures of CRP predicted NT-proBNP levels (<italic>P </italic>&#x0003c; 0.001).</p></sec><sec><title>Conclusion</title><p>CRP levels are linearly associated with levels of NT-proBNP in cross-sectional and longitudinal analyses of patients with RA. The independent associations of NT-proBNP levels and markers of disease activity with clinical cardiovascular endpoints need to be further investigated.</p></sec></abstract></article-meta></front><body><sec><title>Introduction</title><p>Patients with rheumatoid arthritis (RA) have a two- to three-fold increase in cardiovascular mortality and morbidity [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref>]. Several studies have reported an association between disease activity and cardiovascular mortality [<xref ref-type="bibr" rid="B3">3</xref>-<xref ref-type="bibr" rid="B5">5</xref>]. Population-based studies have also shown an increased prevalence of congestive heart failure (CHF) in patients with RA compared with healthy controls and patients with osteoarthritis [<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B7">7</xref>]. Measures of disease activity and severity such as C-reactive protein (CRP), disability index, pain, and global severity are associated with an increased odds ratio for both concurrent and subsequent CHF [<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B8">8</xref>].</p><p>The level of N-terminal pro-brain natriuretic peptide (NT-proBNP) predicts cardiac mortality and morbidity in the general population as well as in cohorts of patients with heart failure and stable coronary heart disease [<xref ref-type="bibr" rid="B9">9</xref>-<xref ref-type="bibr" rid="B12">12</xref>]. NT-proBNP, the biologically inactive N-terminal fragment of the active hormone BNP, has a longer half-life than the active hormone and is a viable biomarker of cardiovascular disease (CVD) [<xref ref-type="bibr" rid="B13">13</xref>]. In the healthy heart, the main site of BNP production is in the atrial cardiomyocytes, but as the heart fails fetal gene programs are activated and the ventricular myocardium becomes the main site of BNP production, releasing the peptide in response to stretch or ischemia [<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B14">14</xref>].</p><p>The associations between clinical and laboratory markers of RA disease activity and levels of NT-proBNP have not been examined. There is also a lack of knowledge on the relationship between exposure to drugs used in the treatment of RA (glucocorticoids, disease-modifying anti-rheumatic drugs [DMARDs], non-steroidal anti-inflammatory drugs [NSAIDs], and cyclooxygenase-2 [COX-2] inhibitors) and NT-proBNP levels in patients with RA. Our objective, therefore, was to examine the cross-sectional and longitudinal associations between markers of inflammation, RA disease activity, medication used, and NT-proBNP levels (dependent variable).</p></sec><sec sec-type="materials|methods"><title>Materials and methods</title><sec><title>Patients</title><p>We followed 238 patients with RA of less than 4 years in duration longitudinally with comprehensive assessments of clinical and radiographic data at baseline and after 5 and 10 years [<xref ref-type="bibr" rid="B15">15</xref>]. The patients had all been recruited to the EUropean Research on Incapacitating DIsease and Social Support (EURIDISS) project, which was initially established in 1991. The project has been approved by the Norwegian Regional Committee for Research Ethics. All patients have signed an informed consent form on inclusion and at each follow-up assessment. At baseline, mean (range) age was 51.6 years (23 to 70), mean (standard deviation, SD) disease duration was 2.3 years (1.2), and 73.5% were female. Serum samples were collected from 237 patients at baseline, 126 patients after 5 years, and 145 after 10 years. Eighty-nine patients were lost to follow-up at the 10-year visit (42 declined to participate, 5 had moved out of the area, 35 had died, and 7 gave other reasons not to participate).</p></sec><sec><title>Measures of disease activity</title><p>Disease activity was measured by joint tenderness, which was assessed at all examinations, and the Ritchie score was calculated [<xref ref-type="bibr" rid="B16">16</xref>]. Swollen joint counts were included at the 5- and 10-year assessments; that is, the disease activity score of 28 joints (DAS28) was not available from the baseline visit [<xref ref-type="bibr" rid="B17">17</xref>]. Surrogate measures of cumulative disease activity were health status and joint destruction. Health status was measured by the self-administered Stanford Health Assessment Questionnaire (HAQ) and the Arthritis Impact Measurement Scales 1 (AIMS1) [<xref ref-type="bibr" rid="B18">18</xref>,<xref ref-type="bibr" rid="B19">19</xref>]. Joint destruction was measured by radiographic damage of the hands and scored according to the van der Heijde modified Sharp criteria (referred to below as the Sharp score) [<xref ref-type="bibr" rid="B20">20</xref>]. Comorbidities were recorded by a trained study nurse at the 5- and 10-year follow-ups using a checklist modified from AIMS1 concerning the presence of 16 possible comorbidities. One of these items addresses the presence of angina, myocardial infarction, or other cardiac diseases. At the 10-year follow-up, known risk factors of CVD (hypertension, cholesterol, smoking, and creatinine) were also recorded. The use of NSAIDs, DMARDs, and glucocorticoids was recorded by the study nurse at all assessments (the use of COX-2 inhibitors was recorded only at the 10-year follow-up).</p></sec><sec><title>Biomarkers</title><p>NT-proBNP was measured using a Modular E 170 device (Roche Diagnostics, Mannheim, Germany). The erythrocyte sedimentation rate was analyzed by the Westergren method at the time of examination, whereas the other biological markers were analyzed from frozen serum or plasma anti-cyclic citrullinated peptide antibody (anti-CCP) by enzyme-linked immunosorbent assay (ELISA) (Inova Diagnostics, San Diego, CA, USA) and CRP by phyCardioPhase high-sensitivity CRP nefelometri (Dade Behring, now part of Siemens AG, Munich, Germany). Rheumatoid factor (RF) IgM was analyzed using the ELISA method [<xref ref-type="bibr" rid="B21">21</xref>].</p></sec><sec><title>Statistical analyses</title><p>NT-proBNP levels were dichotomized according to the national gender- and age-adjusted reference levels modified from Roche Diagnostics guidelines [<xref ref-type="bibr" rid="B22">22</xref>] (female: &#x0003c; 50 years of age, NT-proBNP &#x02264; 20 pmol/L; 50 to 70 years of age, &#x02264; 30 pmol/L; &#x0003e; 70 to 80 years of age, &#x02264; 100 pmol/L, and &#x0003e; 80 years of age, &#x02264; 200 pmol/L; male: &#x0003c; 50 years of age, NT-proBNP &#x02264; 10 pmol/L; 50 to 70 years of age, &#x02264; 20 pmol/L; &#x0003e; 70 to 80 years of age, &#x02264; 60 pmol/L, and &#x0003e; 80 years of age, &#x02264; 100 pmol/L). Groups were compared using the &#x003c7;<sup>2 </sup>and Mann-Whitney <italic>U </italic>tests as appropriate.</p><p>In the regression analyses, NT-proBNP was entered as a continuous dependent variable and was log-transformed to obtain normality. The presented &#x003b2;-coefficients have been transformed from the log value. All other variables were entered untransformed, and all analyses were adjusted for age and gender. The baseline cross-sectional associations between demographic, disease activity, and severity variables (gender, age, CRP, Sharp score of hands, Ritchie score, HAQ disease duration, RF IgM, anti-CCP, and use of DMARDs, steroids, or NSAIDs) and NT-proBNP levels were explored in bivariate linear regression analyses. Variables that were associated (<italic>P </italic>&#x0003c; 0.10) with NT-proBNP were then entered into a multivariate linear regression model and subsequently removed in a stepwise manner according to levels of significance. These analytic procedures were also applied to the cross-sectional data from the 10-year follow-up examination, which gave the opportunity of controlling not only for cardiovascular risk factors, including body mass index (BMI) and creatinine levels, but also for the presence of self-reported CVD.</p><p>Mixed model linear regression was used to examine longitudinal associations [<xref ref-type="bibr" rid="B23">23</xref>]. This is a longitudinal linear regression analysis that controls for multiple testing of the same patient by modelling the covariance between the repeated measurements of each individual as a clustered random effect. An unstructured covariance matrix was used in our analysis assuming that the correlation for each level of within-subject factors is different. The intra-subject variance is then used to calculate the standard error of the regression coefficient. The mixed model procedure deals with missing values by assuming them to be missing at random without removing the individual from the dataset. We investigated the change in NT-proBNP levels over time and examined associations between measures of inflammation, RA disease activity, medication taken, known CVD risk factors, and NT-proBNP (dependent variable). All analyses were performed using SPSS version 14 (SPSS Inc., Chicago, IL, USA). <italic>P </italic>values of less than 0.05 were considered significant.</p></sec></sec><sec><title>Results</title><p>At baseline, 35 patients had pathological levels of NT-proBNP. Disease characteristics were similar between these subgroups (normal versus elevated NT-proBNP), although the group with elevated NT-proBNP levels had significantly higher CRP levels (Table <xref ref-type="table" rid="T1">1</xref>). CRP levels at baseline were significantly associated with NT-proBNP in the linear regression analyses (Table <xref ref-type="table" rid="T2">2</xref>). This significant association was also maintained in the multivariate linear regression analyses, which included the interaction between age and gender as an effect modifier. The use of DMARDs, NSAIDs, or glucocorticoids was not significantly associated with NT-proBNP levels. The analysis was repeated with glucocorticoid use dichotomized according to a dosage greater than or less than 7.5 mg (<italic>P </italic>= 0.189).</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Baseline characteristics with comparison between patients with pathological versus normal levels of NT-proBNP</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="center">All patients</td><td align="center">NT-proBNP-negative<sup>a </sup>n = 202</td><td align="center">NT-proBNP-positive<sup>a </sup>n = 35</td><td align="center"><italic>P </italic>value</td></tr></thead><tbody><tr><td align="left">Age, years</td><td align="center">51.9 (13.0)</td><td align="center">51.4 (12.9)</td><td align="center">54.3 (13.7)</td><td align="center">0.17</td></tr><tr><td align="left">Female gender</td><td align="center">175 (73.5)</td><td align="center">151 (74.8)</td><td align="center">23 (65.7)</td><td align="center">0.26</td></tr><tr><td align="left">Disease duration, years</td><td align="center">2.3 (1.2)</td><td align="center">2.2 (1.1)</td><td align="center">2.4 (1.3)</td><td align="center">0.41</td></tr><tr><td align="left">RF IgM-positive, &#x02265; 25</td><td align="center">114 (47.9)</td><td align="center">97 (48.0)</td><td align="center">16 (45.7)</td><td align="center">0.80</td></tr><tr><td align="left">Anti-CCP-positive, &#x02265; 25</td><td align="center">144 (60.5)</td><td align="center">125 (61.9)</td><td align="center">18 (51.4)</td><td align="center">0.24</td></tr><tr><td align="left">Sharp score</td><td align="center">6.8 (11.8)</td><td align="center">6.8 (12.3)</td><td align="center">6.5 (8.1)</td><td align="center">0.20</td></tr><tr><td align="left">C-reactive protein, mg/L</td><td align="center">9.9 (12.7)</td><td align="center">9.2 (11.8)</td><td align="center">13.9 (15.8)</td><td align="center">0.05</td></tr><tr><td align="left">DMARD user</td><td align="center">124 (52.1)</td><td align="center">104 (51.5)</td><td align="center">19 (54.3)</td><td align="center">0.76</td></tr><tr><td align="left">NSAID user</td><td align="center">109 (45.8</td><td align="center">92 (45.5)</td><td align="center">17 (48.6)</td><td align="center">0.74</td></tr><tr><td align="left">Glucocorticoid user, oral</td><td align="center">65 (27.2)</td><td align="center">51 (25.2)</td><td align="center">14 (40)</td><td align="center">0.07</td></tr></tbody></table><table-wrap-foot><p>Values are presented as mean (standard deviation) for continuous variables and as number (percentage) for counts. <sup>a</sup>Age- and gender-adjusted reference levels. anti-CCP, anti-cyclic citrullinated peptide antibody; DMARD, disease-modifying anti-rheumatic drug; NSAID, non-steroidal anti-inflammatory drug; NT-proBNP, N-terminal pro-brain natriuretic peptide; RF, rheumatoid factor; Sharp score, van der Heijde modified Sharp criteria.</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Cross-sectional associations at baseline between NT-proBNP (dependent variable) and rheumatoid arthritis disease activity</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="center" colspan="2">Adjusted linear regression</td><td align="center" colspan="2">Multivariate linear regression</td></tr></thead><tbody><tr><td></td><td align="center">&#x003b2; coefficient</td><td align="center"><italic>P </italic>value</td><td align="center">&#x003b2; coefficient</td><td align="center"><italic>P </italic>value</td></tr><tr><td colspan="5"><hr></hr></td></tr><tr><td align="left">Age</td><td align="center">1.02 (1.01&#x02013;1.03)</td><td align="center">&#x0003c; 0.001</td><td align="center">1.009 (1.00&#x02013;1.02)</td><td align="center">0.04</td></tr><tr><td align="left">Male gender</td><td align="center">0.74 (0.59&#x02013;0.95)</td><td align="center">0.02</td><td align="center">0.10 (0.04&#x02013;0.23)</td><td align="center">&#x0003c; 0.001</td></tr><tr><td align="left">C-reactive protein<sup>a</sup></td><td align="center">1.01 (1.01&#x02013;1.02)</td><td align="center">0.002</td><td align="center">1.01 (1.01&#x02013;1.02)</td><td align="center">0.001</td></tr><tr><td align="left">RF IgM-positive<sup>a, b</sup></td><td align="center">0.96 (0.79&#x02013;1.17)</td><td align="center">0.67</td><td></td><td></td></tr><tr><td align="left">Anti-CCP-positive<sup>a, b</sup></td><td align="center">0.90 (0.74&#x02013;1.10)</td><td align="center">0.30</td><td></td><td></td></tr><tr><td align="left">Gluocorticoid user<sup>a, b</sup></td><td align="center">1.17 (0.94&#x02013;1.48)</td><td align="center">0.16</td><td></td><td></td></tr><tr><td align="left">DMARD user<sup>a, b</sup></td><td align="center">1.04 (0.85&#x02013;1.26)</td><td align="center">0.71</td><td></td><td></td></tr><tr><td align="left">NSAID user<sup>a, b</sup></td><td align="center">0.97 (0.80&#x02013;1.19)</td><td align="center">0.81</td><td></td><td></td></tr><tr><td align="left">Ritchie score<sup>a</sup></td><td align="center">1.01 (0.99&#x02013;1.03)</td><td align="center">0.21</td><td></td><td></td></tr><tr><td align="left">HAQ<sup>a</sup></td><td align="center">1.06 (0.90&#x02013;1.24)</td><td align="center">0.47</td><td></td><td></td></tr><tr><td align="left">Sharp score<sup>a</sup></td><td align="center">1.00 (0.99&#x02013;1.02)</td><td align="center">0.93</td><td></td><td></td></tr><tr><td align="left">Disease duration<sup>a</sup></td><td align="center">0.99 (0.91&#x02013;1.08)</td><td align="center">0.82</td><td></td><td></td></tr><tr><td align="left">Age &#x000d7; male gender</td><td></td><td></td><td align="center">1.04 (1.02&#x02013;1.05)</td><td align="center">&#x0003c; 0.001</td></tr><tr><td colspan="5"><hr></hr></td></tr><tr><td align="left"><italic>R</italic><sup>2 </sup>adjusted</td><td></td><td></td><td align="center">0.23</td><td align="center">&#x0003c; 0.05</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Age- and gender-adjusted; <sup>b</sup>dichotomized variable. anti-CCP, anti-cyclic citrullinated peptide antibody; DMARD, disease-modifying anti-rheumatic drug; HAQ, Stanford Health Assessment Questionnaire; NSAID, non-steroidal anti-inflammatory drug; NT-proBNP, N-terminal pro-brain natriuretic peptide; RF, rheumatoid factor; Ritchie score, Ritchie articular index; Sharp score, van der Heijde modified Sharp criteria.</p></table-wrap-foot></table-wrap><p>At the 10-year follow-up examination, age, gender, BMI, creatinine, CRP, and disease duration were significantly associated with NT-proBNP levels (Table <xref ref-type="table" rid="T3">3</xref>). Consistent with our baseline analyses, CRP and NT-proBNP levels remained significantly associated in the multivariate analysis. The significant association between disease duration and NT-proBNP levels was also maintained. The model was also valid if self-reported CVD was entered as a covariate (&#x003b2; coefficient for CVD 1.65, 95% confidence interval [CI] 1.15 to 2.37; <italic>P </italic>= 0.007). The presence of hypertension, smoking status, and prevalent use of glucocorticoids, DMARDs (including subgroups of tumor necrosis factor [TNF] inhibitors and methotrexate users), COX-2 inhibitors, or NSAIDs was not significantly associated with NT-proBNP levels (data not shown).</p><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Cross-sectional associations at the 10-year follow-up between NT-proBNP (dependent variable) and rheumatoid arthritis disease activity, controlling for cardiovascular risk factors</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="center" colspan="2">Adjusted linear regression</td><td align="center" colspan="2">Multivariate linear regression</td></tr></thead><tbody><tr><td></td><td align="center">&#x003b2; coefficients</td><td align="center"><italic>P </italic>value</td><td align="center">&#x003b2; coefficients</td><td align="center"><italic>P </italic>value</td></tr><tr><td colspan="5"><hr></hr></td></tr><tr><td align="left">Age</td><td align="center">1.04 (1.03&#x02013;1.05)</td><td align="center">&#x0003c; 0.001</td><td align="center">1.04 (1.03&#x02013;1.05)</td><td align="center">&#x0003c; 0.001</td></tr><tr><td align="left">Male gender</td><td align="center">0.92 (0.64&#x02013;1.31)</td><td align="center">0.64</td><td align="center">0.76 (0.53&#x02013;1.04)</td><td align="center">0.09</td></tr><tr><td align="left">Body mass index<sup>a</sup></td><td align="center">0.96 (0.93&#x02013;0.98)</td><td align="center">0.001</td><td></td><td></td></tr><tr><td align="left">Atherogenic index<sup>a</sup></td><td align="center">0.95 (0.86&#x02013;1.04)</td><td align="center">0.25</td><td></td><td></td></tr><tr><td align="left">Creatinine<sup>a</sup></td><td align="center">1.02 (1.01&#x02013;1.02)</td><td align="center">0.001</td><td align="center">1.01 (1.00&#x02013;1.02)</td><td align="center">0.04</td></tr><tr><td align="left">C-reactive protein<sup>a</sup></td><td align="center">1.01 (1.0&#x02013;1.03)</td><td align="center">0.06</td><td align="center">1.02 (1.00&#x02013;1.02)</td><td align="center">0.03</td></tr><tr><td align="left">RF IgM-positive<sup>a, b</sup></td><td align="center">0.92 (0.72&#x02013;1.19)</td><td align="center">0.53</td><td></td><td></td></tr><tr><td align="left">Anti-CCP-positive<sup>a, b</sup></td><td align="center">1.14 (0.88&#x02013;1.45)</td><td align="center">0.33</td><td></td><td></td></tr><tr><td align="left">Ritchie score<sup>a</sup></td><td align="center">1.00 (0.99&#x02013;1.01)</td><td align="center">0.87</td><td></td><td></td></tr><tr><td align="left">DAS28<sup>a</sup></td><td align="center">1.05 (0.96&#x02013;1.16)</td><td align="center">0.27</td><td></td><td></td></tr><tr><td align="left">HAQ<sup>a</sup></td><td align="center">1.15 (0.94&#x02013;1.41)</td><td align="center">0.17</td><td></td><td></td></tr><tr><td align="left">Sharp score<sup>a</sup></td><td align="center">1.002 (1.00&#x02013;1.01)</td><td align="center">0.17</td><td></td><td></td></tr><tr><td align="left">Disease duration<sup>a</sup></td><td align="center">1.14 (1.02&#x02013;1.27)</td><td align="center">0.02</td><td align="center">1.15 (1.03&#x02013;1.27)</td><td align="center">0.01</td></tr><tr><td colspan="5"><hr></hr></td></tr><tr><td align="left"><italic>R</italic><sup>2 </sup>adjusted</td><td></td><td></td><td align="center">0.38</td><td align="center">&#x0003c; 0.001</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Age- and gender-adjusted; <sup>b</sup>dichotomized variable. anti-CCP, anti-cyclic citrullinated peptide antibody; DAS28, disease activity score of 28 joints; HAQ, Stanford Health Assessment Questionnaire; NT-proBNP, N-terminal pro-brain natriuretic peptide; RF, rheumatoid factor; Ritchie score, Ritchie articular index; Sharp score, van der Heijde modified Sharp criteria.</p></table-wrap-foot></table-wrap><p>In the repeated mixed model analysis, several markers of disease activity were associated with NT-proBNP levels, but after multivariate adjustment for time of follow-up, only CRP remained a significant predictor in the final model (Table <xref ref-type="table" rid="T4">4</xref>). NT-proBNP levels increased between each follow-up visit and the interactions between age and gender and gender and time of follow-up were significant effect modifiers. The model remained significant if self-reported CVD at the 10-year follow-up was entered as a covariate (&#x003b2; coefficient for CVD 1.48, 95% CI 1.11 to 1.98; <italic>P </italic>= 0.008).</p><table-wrap position="float" id="T4"><label>Table 4</label><caption><p>Mixed model repeated measure linear regression showing the association between NT-proBNP (dependent variable) and markers of disease activity and treatment</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="center" colspan="2">Adjusted linear regression (CI)</td><td align="center" colspan="2">Multivariate linear regression (CI)</td></tr></thead><tbody><tr><td></td><td align="center">&#x003b2; coefficients (CI)</td><td align="center"><italic>P </italic>value</td><td align="center">&#x003b2; coefficients (CI)</td><td align="center"><italic>P </italic>value</td></tr><tr><td colspan="5"><hr></hr></td></tr><tr><td align="left">Age</td><td align="center">1.03 (1.02&#x02013;1.03)</td><td align="center">&#x0003c; 0.001</td><td align="center">1.02 (1.01&#x02013;1.02)</td><td align="center">&#x0003c; 0.001</td></tr><tr><td align="left">Male gender</td><td align="center">0.81 (0.64&#x02013;1.01)</td><td align="center">0.06</td><td align="center">0.12 (0.05&#x02013;0.26)</td><td align="center">&#x0003c; 0.001</td></tr><tr><td align="left">C-reactive protein<sup>a</sup></td><td align="center">1.01 (1.01&#x02013;1.02)</td><td align="center">&#x0003c; 0.001</td><td align="center">1.01 (1.01&#x02013;1.02)</td><td align="center">&#x0003c; 0.001</td></tr><tr><td align="left">HAQ<sup>a</sup></td><td align="center">1.12 (1.00&#x02013;1.27)</td><td align="center">0.06</td><td></td><td></td></tr><tr><td align="left">Prednisolone<sup>a, b</sup></td><td align="center">1.20 (1.03&#x02013;1.41)</td><td align="center">0.02</td><td></td><td></td></tr><tr><td align="left">NSAID<sup>a, b</sup></td><td align="center">0.90 (0.79&#x02013;1.04)</td><td align="center">0.14</td><td></td><td></td></tr><tr><td align="left">DMARD<sup>a, b</sup></td><td align="center">0.95 (0.83&#x02013;1.09)</td><td align="center">0.49</td><td></td><td></td></tr><tr><td align="left">Sharp score<sup>a</sup></td><td align="center">1.01 (1.00&#x02013;1.01)</td><td align="center">0.001</td><td></td><td></td></tr><tr><td align="left">Ritchie score<sup>a</sup></td><td align="center">1.01 (1.00&#x02013;1.02)</td><td align="center">0.01</td><td></td><td></td></tr><tr><td align="left">Time</td><td align="center">1.04 (1.03&#x02013;1.06)</td><td align="center">&#x0003c; 0.001</td><td align="center">1.03 (1.02&#x02013;1.05)</td><td align="center">&#x0003c; 0.001</td></tr><tr><td align="left">Time &#x000d7; male gender</td><td></td><td></td><td align="center">1.04 (1.01&#x02013;1.07)</td><td align="center">0.01</td></tr><tr><td align="left">Age &#x000d7; male gender</td><td></td><td></td><td align="center">1.03 (1.02&#x02013;1.05)</td><td align="center">0.01</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Age- and gender-adjusted; <sup>b</sup>dichotomized variable. CI, confidence interval; DMARD, disease-modifying anti-rheumatic drug; HAQ, Stanford Health Assessment Questionnaire; NSAID, non-steroidal anti-inflammatory drug; NT-proBNP, N-terminal pro-brain natriuretic peptide; Ritchie score, Ritchie articular index; Sharp score, van der Heijde modified Sharp criteria.</p></table-wrap-foot></table-wrap></sec><sec><title>Discussion</title><p>NT-proBNP has been shown to be an independent predictor of cardiovascular morbidity and mortality [<xref ref-type="bibr" rid="B9">9</xref>-<xref ref-type="bibr" rid="B11">11</xref>], and disease activity in RA correlates with mortality, CVD, and CHF [<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B6">6</xref>]. Hence, it is of interest to investigate how markers of inflammation and disease activity are related to NT-proBNP in a longitudinal perspective. We found significant cross-sectional and longitudinal associations between CRP and levels of NT-proBNP in this cohort of RA patients with less than 4 years of disease duration at inclusion. CRP remained an independent predictor of NT-proBNP levels after controlling for known cardiovascular risk factors and the presence of self-reported CVD at the 10-year follow-up and in the longitudinal analyses.</p><p>Our findings are intriguing as the relationship between BNP/NT-proBNP values and the risk of CVD may not be dependent on a threshold value of BNP/NT-proBNP but rather represents a continuum [<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B24">24</xref>]. Wang and colleagues [<xref ref-type="bibr" rid="B11">11</xref>] found that a single measurement of BNP provided prognostic information in an unselected population of 3,346 persons without heart failure followed for a mean of 5.2 years. An increase of BNP levels by 1 SD was associated with a 77% increased risk of developing heart failure and a 28% increased risk of a first cardiovascular event [<xref ref-type="bibr" rid="B11">11</xref>]. BNP has been validated as a marker of CVD in patients with RA. Harney and colleagues [<xref ref-type="bibr" rid="B25">25</xref>] found that BNP levels were significantly higher in 26 patients with RA than in controls and correlated with end diastolic volume (<italic>r</italic><sup>2 </sup>= 0.83), end systolic volume (<italic>r</italic><sup>2 </sup>= 0.62), and left ventricular mass (<italic>r</italic><sup>2 </sup>= 0.4). Levels of NT-proBNP have been found to correlate closely with BNP (<italic>r </italic>= 0.9; <italic>P </italic>&#x0003c; 0.001) [<xref ref-type="bibr" rid="B24">24</xref>].</p><p>Increased levels of inflammatory markers are associated with an increased risk of cardiovascular morbidity and mortality [<xref ref-type="bibr" rid="B26">26</xref>,<xref ref-type="bibr" rid="B27">27</xref>]. We found that CRP was significantly associated with levels of NT-proBNP at all time points. Flares in inflammatory activity might be better predictors of cardiovascular events than long-term exposure to low-grade inflammation. Indeed, there is evidence that the initiation of CHF in RA patients is preceded by a flare in disease activity [<xref ref-type="bibr" rid="B8">8</xref>]. Radiographic progression and the HAQ score are surrogate measures of cumulative disease activity, although we acknowledge that there are wide inter-individual variations [<xref ref-type="bibr" rid="B28">28</xref>-<xref ref-type="bibr" rid="B31">31</xref>]. We found no significant association between these measures and NT-proBNP levels in our multivariate longitudinal analyses. Previous reports on the association between joint destruction and CVD in RA have been inconsistent; W&#x000e5;llberg-Jonsson and colleagues [<xref ref-type="bibr" rid="B5">5</xref>] demonstrated that early progression of erosions increased the risk of cardiovascular events. Solomon and colleagues [<xref ref-type="bibr" rid="B1">1</xref>], on the other hand, did not find that joint erosions were significantly associated with cardiovascular death or myocardial infarction in multivariate analyses. However, we did find disease duration to be significantly associated with NT-proBNP levels at the 10-year cross-sectional analysis. As all patients had a disease duration of 4 years or less at inclusion, the correlation with NT-proBNP levels after 10 years is difficult to interpret. A link between RA disease duration and increased CVD risk can be questioned. In the Rochester cohort, no association was found between risk of heart failure or cardiovascular death and RA disease duration [<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B32">32</xref>], nor did Book and colleagues [<xref ref-type="bibr" rid="B33">33</xref>] find an association between disease duration and mortality.</p><p>To our knowledge, no previous study has examined the association between markers of inflammation in RA and BNP/NT-proBNP. It could be argued that the association between CRP and NT-proBNP identified in our study is a consequence of the inflammatory nature of ventricular remodelling. Patients with RA are not only exposed to systemic inflammation from their arthritic disease, the failing heart itself may be invaded by peripheral blood mononuclear cells that participate in left ventricular remodelling. These and other inflammatory cells release TNF-&#x003b1; and interleukin-6, thereby increasing CRP levels through upregulation of hepatic synthesis [<xref ref-type="bibr" rid="B27">27</xref>].</p><p>The strength of the present study is the prospective longitudinal design with regular clinical examinations, blood sampling with subsequent batch analyses, and documentation of radiographic progression. NT-proBNP has been shown to tolerate routine laboratory handling and may be analyzed from frozen sera [<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B34">34</xref>]. The validity of our model is supported by the association between NT-proBNP levels and self-reported CVD. Furthermore, in agreement with previous studies, creatinine levels predict NT-proBNP in the final model. NT-proBNP is metabolized in the renal proximal tubule, and reduced renal function partially accounts for the age-related increase in NT-proBNP levels in the general population [<xref ref-type="bibr" rid="B14">14</xref>,<xref ref-type="bibr" rid="B35">35</xref>]. We found BMI to be inversely correlated with NT-proBNP levels in the adjusted bivariate analyses although it did not reach significance in the multivariate analysis. Other studies have confirmed the inverse relationship between BMI and NT-proBNP levels [<xref ref-type="bibr" rid="B36">36</xref>].</p><p>This study has several shortcomings. Two hundred thirty-eight patients were included at baseline, and 145 completed the 10-year follow-up. The small scale of this study is a limitation in the analyses. CVD in RA was not a major focus when the cohort was established, and information relating to cardiovascular comorbidity, smoking, concomitant medication, blood pressure, or BMI was not recorded at baseline. The presence of CVD was recorded by a questionnaire at the 10-year follow-up and we did not have the opportunity to verify the diagnosis by searching the medical records. Cause of death for the 35 patients who died during the study was not recorded. Thus, we considered that the data were not sufficiently robust to allow an explorative analysis of how levels of NT-proBNP predict future CVD. However, the patients were requested to report current medication. There was perfect agreement between self-reported CVD and the reported prescription of medication typically used to treat CVD, such as anti-hypertensive drugs, anti-platelet agents, or nitrates, allowing for an internal consistency check.</p></sec><sec><title>Conclusion</title><p>CRP levels were linearly associated with levels of NT-proBNP in this cross-sectional and longitudinal study of 238 patients with RA. Further studies are needed to elucidate how this biomarker can be implemented in clinical decision making in RA.</p></sec><sec><title>Abbreviations</title><p>AIMS1 = Arthritis Impact Measurement Scales 1; anti-CCP = anti-cyclic citrullinated peptide antibody; BMI = body mass index; BNP = brain natriuretic peptide; CHF = congestive heart failure; CI = confidence interval; COX-2 = cyclooxygenase-2; CRP = C-reactive protein; CVD = cardiovascular disease; DAS28 = disease activity score of 28 joints; DMARD = disease-modifying anti-rheumatic drug; ELISA = enzyme-linked immunosorbent assay; HAQ = Stanford Health Assessment Questionnaire; NSAID = non-steroidal anti-inflammatory drug; NT-proBNP = N-terminal pro-brain natriuretic peptide; RA = rheumatoid arthritis; RF = rheumatoid factor; SD = standard deviation; Sharp score = van der Heijde modified Sharp criteria; TNF = tumor necrosis factor.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>SAP developed the study, performed the analyses, and drafted the manuscript. KA participated in the development of the study and in the drafting of the manuscript. S&#x000d8; participated in the data collection and the drafting of the manuscript. PM gave statistical advice and helped in the drafting of the manuscript. DA conceived the study, participated in its design and development, and helped in the drafting of the manuscript. TKK conceived the study, participated in its design and development, and helped in the drafting of the manuscript. All authors have read and approved the manuscript.</p></sec></body><back><ack><sec><title>Acknowledgements</title><p>We thank Roche Diagnostics (Mannheim, Germany) for providing the kits for NT-proBNP testing (Bernhard Trauth), Inge Christoffer Olsen for statistical help, and Ludvig Daae for helpful comments. This study was supported by grants from the Eastern Norway Regional Health Authority, The Norwegian Rheumatism Association, The Norwegian Women Public Health Association, the Grethe Harbitz Legacy, and the Marie and Else Mustad's Legacy.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Solomon</surname><given-names>DH</given-names></name><name><surname>Karlson</surname><given-names>EW</given-names></name><name><surname>Rimm</surname><given-names>EB</given-names></name><name><surname>Cannuscio</surname><given-names>CC</given-names></name><name><surname>Mandl</surname><given-names>LA</given-names></name><name><surname>Manson</surname><given-names>JE</given-names></name><name><surname>Stampfer</surname><given-names>MJ</given-names></name><name><surname>Curhan</surname><given-names>GC</given-names></name></person-group><article-title>Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis</article-title><source>Circulation</source><year>2003</year><volume>107</volume><fpage>1303</fpage><lpage>1307</lpage><pub-id pub-id-type="pmid">12628952</pub-id><pub-id pub-id-type="doi">10.1161/01.CIR.0000054612.26458.B2</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>del Rinc&#x000f3;n</surname><given-names>ID</given-names></name><name><surname>Williams</surname><given-names>K</given-names></name><name><surname>Stern</surname><given-names>MP</given-names></name><name><surname>Freeman</surname><given-names>GL</given-names></name><name><surname>Escalante</surname><given-names>A</given-names></name></person-group><article-title>High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors</article-title><source>Arthritis Rheum</source><year>2001</year><volume>44</volume><fpage>2737</fpage><lpage>2745</lpage><pub-id pub-id-type="pmid">11762933</pub-id><pub-id pub-id-type="doi">10.1002/1529-0131(200112)44:12&#x0003c;2737::AID-ART460&#x0003e;3.0.CO;2-#</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Turesson</surname><given-names>C</given-names></name><name><surname>McClelland</surname><given-names>RL</given-names></name><name><surname>Christianson</surname><given-names>TJ</given-names></name><name><surname>Matteson</surname><given-names>EL</given-names></name></person-group><article-title>Severe extra-articular disease manifestations are associated with an increased risk of first ever cardiovascular events in patients with rheumatoid arthritis</article-title><source>Ann Rheum Dis</source><year>2007</year><volume>66</volume><fpage>70</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">16877533</pub-id><pub-id pub-id-type="doi">10.1136/ard.2006.052506</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Farragher</surname><given-names>TM</given-names></name><name><surname>Lunt</surname><given-names>M</given-names></name><name><surname>Bunn</surname><given-names>DK</given-names></name><name><surname>Silman</surname><given-names>AJ</given-names></name><name><surname>Symmons</surname><given-names>DP</given-names></name></person-group><article-title>Early functional disability predicts both all-cause and cardiovascular mortality in people with inflammatory polyarthritis: results from the Norfolk Arthritis Register</article-title><source>Ann Rheum Dis</source><year>2007</year><volume>66</volume><fpage>486</fpage><lpage>492</lpage><pub-id pub-id-type="pmid">17090565</pub-id><pub-id pub-id-type="doi">10.1136/ard.2006.056390</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>W&#x000e5;llberg-Jonsson</surname><given-names>S</given-names></name><name><surname>Johansson</surname><given-names>H</given-names></name><name><surname>Ohman</surname><given-names>ML</given-names></name><name><surname>Rantap&#x000e4;&#x000e4;-Dahlqvist</surname><given-names>S</given-names></name></person-group><article-title>Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset</article-title><source>J Rheumatol</source><year>1999</year><volume>26</volume><fpage>2562</fpage><lpage>2571</lpage><pub-id pub-id-type="pmid">10606363</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wolfe</surname><given-names>F</given-names></name><name><surname>Michaud</surname><given-names>K</given-names></name></person-group><article-title>Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy</article-title><source>Am J Med</source><year>2004</year><volume>116</volume><fpage>305</fpage><lpage>311</lpage><pub-id pub-id-type="pmid">14984815</pub-id><pub-id pub-id-type="doi">10.1016/j.amjmed.2003.09.039</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nicola</surname><given-names>PJ</given-names></name><name><surname>Maradit-Kremers</surname><given-names>H</given-names></name><name><surname>Roger</surname><given-names>VL</given-names></name><name><surname>Jacobsen</surname><given-names>SJ</given-names></name><name><surname>Crowson</surname><given-names>CS</given-names></name><name><surname>Ballman</surname><given-names>KV</given-names></name><name><surname>Gabriel</surname><given-names>SE</given-names></name></person-group><article-title>The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years</article-title><source>Arthritis Rheum</source><year>2005</year><volume>52</volume><fpage>412</fpage><lpage>420</lpage><pub-id pub-id-type="pmid">15692992</pub-id><pub-id pub-id-type="doi">10.1002/art.20855</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Maradit-Kremers</surname><given-names>H</given-names></name><name><surname>Nicola</surname><given-names>PJ</given-names></name><name><surname>Crowson</surname><given-names>CS</given-names></name><name><surname>Ballman</surname><given-names>KV</given-names></name><name><surname>Jacobsen</surname><given-names>SJ</given-names></name><name><surname>Roger</surname><given-names>VL</given-names></name><name><surname>Gabriel</surname><given-names>SE</given-names></name></person-group><article-title>Raised erythrocyte sedimentation rate signals heart failure in patients with rheumatoid arthritis</article-title><source>Ann Rheum Dis</source><year>2007</year><volume>66</volume><fpage>76</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">16818462</pub-id><pub-id pub-id-type="doi">10.1136/ard.2006.053710</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bibbins-Domingo</surname><given-names>K</given-names></name><name><surname>Ansari</surname><given-names>M</given-names></name><name><surname>Schiller</surname><given-names>NB</given-names></name><name><surname>Massie</surname><given-names>B</given-names></name><name><surname>Whooley</surname><given-names>MA</given-names></name></person-group><article-title>B-type natriuretic peptide and ischemia in patients with stable coronary disease: data from the Heart and Soul study</article-title><source>Circulation</source><year>2003</year><volume>108</volume><fpage>2987</fpage><lpage>2992</lpage><pub-id pub-id-type="pmid">14662720</pub-id><pub-id pub-id-type="doi">10.1161/01.CIR.0000103681.04726.9C</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kragelund</surname><given-names>C</given-names></name><name><surname>Gronning</surname><given-names>B</given-names></name><name><surname>Kober</surname><given-names>L</given-names></name><name><surname>Hildebrandt</surname><given-names>P</given-names></name><name><surname>Steffensen</surname><given-names>R</given-names></name></person-group><article-title>N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease</article-title><source>N Engl J Med</source><year>2005</year><volume>352</volume><fpage>666</fpage><lpage>675</lpage><pub-id pub-id-type="pmid">15716560</pub-id><pub-id pub-id-type="doi">10.1056/NEJMoa042330</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>TJ</given-names></name><name><surname>Larson</surname><given-names>MG</given-names></name><name><surname>Levy</surname><given-names>D</given-names></name><name><surname>Benjamin</surname><given-names>EJ</given-names></name><name><surname>Leip</surname><given-names>EP</given-names></name><name><surname>Omland</surname><given-names>T</given-names></name><name><surname>Wolf</surname><given-names>PA</given-names></name><name><surname>Vasan</surname><given-names>RS</given-names></name></person-group><article-title>Plasma natriuretic peptide levels and the risk of cardiovascular events and death</article-title><source>N Engl J Med</source><year>2004</year><volume>350</volume><fpage>655</fpage><lpage>663</lpage><pub-id pub-id-type="pmid">14960742</pub-id><pub-id pub-id-type="doi">10.1056/NEJMoa031994</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bettencourt</surname><given-names>P</given-names></name><name><surname>Azevedo</surname><given-names>A</given-names></name><name><surname>Pimenta</surname><given-names>J</given-names></name><name><surname>Frioes</surname><given-names>F</given-names></name><name><surname>Ferreira</surname><given-names>S</given-names></name><name><surname>Ferreira</surname><given-names>A</given-names></name></person-group><article-title>N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients</article-title><source>Circulation</source><year>2004</year><volume>110</volume><fpage>2168</fpage><lpage>2174</lpage><pub-id pub-id-type="pmid">15451800</pub-id><pub-id pub-id-type="doi">10.1161/01.CIR.0000144310.04433.BE</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tschope</surname><given-names>C</given-names></name><name><surname>Kasner</surname><given-names>M</given-names></name><name><surname>Westermann</surname><given-names>D</given-names></name><name><surname>Gaub</surname><given-names>R</given-names></name><name><surname>Poller</surname><given-names>WC</given-names></name><name><surname>Schultheiss</surname><given-names>HP</given-names></name></person-group><article-title>The role of NT-proBNP in the diagnostics of isolated diastolic dysfunction: correlation with echocardiographic and invasive measurements</article-title><source>Eur Heart J</source><year>2005</year><volume>26</volume><fpage>2277</fpage><lpage>2284</lpage><pub-id pub-id-type="pmid">16014646</pub-id><pub-id pub-id-type="doi">10.1093/eurheartj/ehi406</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McKie</surname><given-names>PM</given-names></name><name><surname>Burnett</surname><given-names>JC</given-names><suffix>Jr</suffix></name></person-group><article-title>B-type natriuretic peptide as a biomarker beyond heart failure: speculations and opportunities</article-title><source>Mayo Clin Proc</source><year>2005</year><volume>80</volume><fpage>1029</fpage><lpage>1036</lpage><pub-id pub-id-type="pmid">16092582</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Smedstad</surname><given-names>LM</given-names></name><name><surname>Vaglum</surname><given-names>P</given-names></name><name><surname>Kvien</surname><given-names>TK</given-names></name><name><surname>Moum</surname><given-names>T</given-names></name></person-group><article-title>The relationship between self-reported pain and sociodemographic variables, anxiety, and depressive symptoms in rheumatoid arthritis</article-title><source>J Rheumatol</source><year>1995</year><volume>22</volume><fpage>514</fpage><lpage>520</lpage><pub-id pub-id-type="pmid">7783072</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ritchie</surname><given-names>DM</given-names></name><name><surname>Boyle</surname><given-names>JA</given-names></name><name><surname>McInnes</surname><given-names>JM</given-names></name><name><surname>Jasani</surname><given-names>MK</given-names></name><name><surname>Dalakos</surname><given-names>TG</given-names></name><name><surname>Grieveson</surname><given-names>P</given-names></name><name><surname>Buchanan</surname><given-names>WW</given-names></name></person-group><article-title>Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis</article-title><source>Q J Med</source><year>1968</year><volume>37</volume><fpage>393</fpage><lpage>406</lpage><pub-id pub-id-type="pmid">4877784</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Prevoo</surname><given-names>ML</given-names></name><name><surname>van 't Hof</surname><given-names>MA</given-names></name><name><surname>Kuper</surname><given-names>HH</given-names></name><name><surname>van Leeuwen</surname><given-names>MA</given-names></name><name><surname>Putte</surname><given-names>LB van de</given-names></name><name><surname>van Riel</surname><given-names>PL</given-names></name></person-group><article-title>Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis</article-title><source>Arthritis Rheum</source><year>1995</year><volume>38</volume><fpage>44</fpage><lpage>48</lpage><pub-id pub-id-type="pmid">7818570</pub-id><pub-id pub-id-type="doi">10.1002/art.1780380107</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fries</surname><given-names>JF</given-names></name><name><surname>Spitz</surname><given-names>P</given-names></name><name><surname>Kraines</surname><given-names>RG</given-names></name><name><surname>Holman</surname><given-names>HR</given-names></name></person-group><article-title>Measurement of patient outcome in arthritis</article-title><source>Arthritis Rheum</source><year>1980</year><volume>23</volume><fpage>137</fpage><lpage>145</lpage><pub-id pub-id-type="pmid">7362664</pub-id><pub-id pub-id-type="doi">10.1002/art.1780230202</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meenan</surname><given-names>RF</given-names></name><name><surname>Gertman</surname><given-names>PM</given-names></name><name><surname>Mason</surname><given-names>JH</given-names></name></person-group><article-title>Measuring health status in arthritis. The arthritis impact measurement scales</article-title><source>Arthritis Rheum</source><year>1980</year><volume>23</volume><fpage>146</fpage><lpage>152</lpage><pub-id pub-id-type="pmid">7362665</pub-id><pub-id pub-id-type="doi">10.1002/art.1780230203</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Heijde</surname><given-names>DM van der</given-names></name></person-group><article-title>Plain X-rays in rheumatoid arthritis: overview of scoring methods, their reliability and applicability</article-title><source>Baillieres Clin Rheumatol</source><year>1996</year><volume>10</volume><fpage>435</fpage><lpage>453</lpage><pub-id pub-id-type="pmid">8876953</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Syversen</surname><given-names>SW</given-names></name><name><surname>Gaarder</surname><given-names>PI</given-names></name><name><surname>Goll</surname><given-names>GL</given-names></name><name><surname>&#x000d8;deg&#x000e5;rd</surname><given-names>S</given-names></name><name><surname>Haavardsholm</surname><given-names>EA</given-names></name><name><surname>Mowinckel</surname><given-names>P</given-names></name><name><surname>Heijde</surname><given-names>D van der</given-names></name><name><surname>Landew&#x000e9;</surname><given-names>R</given-names></name><name><surname>Kvien</surname><given-names>TK</given-names></name></person-group><article-title>High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study</article-title><source>Ann Rheum Dis</source><year>2008</year><volume>67</volume><fpage>212</fpage><lpage>217</lpage><pub-id pub-id-type="pmid">17526555</pub-id><pub-id pub-id-type="doi">10.1136/ard.2006.068247</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Raymond</surname><given-names>I</given-names></name><name><surname>Groenning</surname><given-names>BA</given-names></name><name><surname>Hildebrandt</surname><given-names>PR</given-names></name><name><surname>Nilsson</surname><given-names>JC</given-names></name><name><surname>Baumann</surname><given-names>M</given-names></name><name><surname>Trawinski</surname><given-names>J</given-names></name><name><surname>Pedersen</surname><given-names>F</given-names></name></person-group><article-title>The influence of age, sex and other variables on the plasma level of N-terminal pro brain natriuretic peptide in a large sample of the general population</article-title><source>Heart</source><year>2003</year><volume>89</volume><fpage>745</fpage><lpage>751</lpage><pub-id pub-id-type="pmid">12807847</pub-id><pub-id pub-id-type="doi">10.1136/heart.89.7.745</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>YH</given-names></name></person-group><article-title>Biostatistics 301A. Repeated measurement analysis (mixed models)</article-title><source>Singapore Med J</source><year>2004</year><volume>45</volume><fpage>456</fpage><lpage>461</lpage><pub-id pub-id-type="pmid">15455165</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Richards</surname><given-names>M</given-names></name><name><surname>Nicholls</surname><given-names>MG</given-names></name><name><surname>Espiner</surname><given-names>EA</given-names></name><name><surname>Lainchbury</surname><given-names>JG</given-names></name><name><surname>Troughton</surname><given-names>RW</given-names></name><name><surname>Elliott</surname><given-names>J</given-names></name><name><surname>Frampton</surname><given-names>CM</given-names></name><name><surname>Crozier</surname><given-names>IG</given-names></name><name><surname>Yandle</surname><given-names>TG</given-names></name><name><surname>Doughty</surname><given-names>R</given-names></name><name><surname>MacMahon</surname><given-names>S</given-names></name><name><surname>Sharpe</surname><given-names>N</given-names></name><collab>Christchurch Cardioendocrine Research Group; Australia-New Zealand Heart Failure Group</collab></person-group><article-title>Comparison of B-type natriuretic peptides for assessment of cardiac function and prognosis in stable ischemic heart disease</article-title><source>J Am Coll Cardiol</source><year>2006</year><volume>47</volume><fpage>52</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">16386664</pub-id><pub-id pub-id-type="doi">10.1016/j.jacc.2005.06.085</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Harney</surname><given-names>SM</given-names></name><name><surname>Timperley</surname><given-names>J</given-names></name><name><surname>Daly</surname><given-names>C</given-names></name><name><surname>Harin</surname><given-names>A</given-names></name><name><surname>James</surname><given-names>T</given-names></name><name><surname>Brown</surname><given-names>MA</given-names></name><name><surname>Banning</surname><given-names>AP</given-names></name><name><surname>Fox</surname><given-names>K</given-names></name><name><surname>Donnelly</surname><given-names>S</given-names></name><name><surname>Wordsworth</surname><given-names>BP</given-names></name></person-group><article-title>Brain natriuretic peptide is a potentially useful screening tool for the detection of cardiovascular disease in patients with rheumatoid arthritis</article-title><source>Ann Rheum Dis</source><year>2006</year><volume>65</volume><fpage>136</fpage><pub-id pub-id-type="pmid">16344502</pub-id><pub-id pub-id-type="doi">10.1136/ard.2005.040634</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ridker</surname><given-names>PM</given-names></name><name><surname>Buring</surname><given-names>JE</given-names></name><name><surname>Cook</surname><given-names>NR</given-names></name><name><surname>Rifai</surname><given-names>N</given-names></name></person-group><article-title>C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women</article-title><source>Circulation</source><year>2003</year><volume>107</volume><fpage>391</fpage><lpage>397</lpage><pub-id pub-id-type="pmid">12551861</pub-id><pub-id pub-id-type="doi">10.1161/01.CIR.0000055014.62083.05</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vasan</surname><given-names>RS</given-names></name><name><surname>Sullivan</surname><given-names>LM</given-names></name><name><surname>Roubenoff</surname><given-names>R</given-names></name><name><surname>Dinarello</surname><given-names>CA</given-names></name><name><surname>Harris</surname><given-names>T</given-names></name><name><surname>Benjamin</surname><given-names>EJ</given-names></name><name><surname>Sawyer</surname><given-names>DB</given-names></name><name><surname>Levy</surname><given-names>D</given-names></name><name><surname>Wilson</surname><given-names>PW</given-names></name><name><surname>D'Agostino</surname><given-names>RB</given-names></name><collab>Framingham Heart Study</collab></person-group><article-title>Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study</article-title><source>Circulation</source><year>2003</year><volume>107</volume><fpage>1486</fpage><lpage>1491</lpage><pub-id pub-id-type="pmid">12654604</pub-id><pub-id pub-id-type="doi">10.1161/01.CIR.0000057810.48709.F6</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van Leeuwen</surname><given-names>MA</given-names></name><name><surname>van Rijswijk</surname><given-names>MH</given-names></name><name><surname>Heijde</surname><given-names>DM van der</given-names></name><name><surname>Te Meerman</surname><given-names>GJ</given-names></name><name><surname>van Riel</surname><given-names>PL</given-names></name><name><surname>Houtman</surname><given-names>PM</given-names></name><name><surname>Putte</surname><given-names>LB van De</given-names></name><name><surname>Limburg</surname><given-names>PC</given-names></name></person-group><article-title>The acute-phase response in relation to radiographic progression in early rheumatoid arthritis: a prospective study during the first three years of the disease</article-title><source>Br J Rheumatol</source><year>1993</year><volume>32</volume><issue>Suppl 3</issue><fpage>9</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">8508266</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wick</surname><given-names>MC</given-names></name><name><surname>Lindblad</surname><given-names>S</given-names></name><name><surname>Klareskog</surname><given-names>L</given-names></name><name><surname>Van Vollenhoven</surname><given-names>RF</given-names></name></person-group><article-title>Relationship between inflammation and joint destruction in early rheumatoid arthritis: a mathematical description</article-title><source>Ann Rheum Dis</source><year>2004</year><volume>63</volume><fpage>848</fpage><lpage>852</lpage><pub-id pub-id-type="pmid">15194582</pub-id><pub-id pub-id-type="doi">10.1136/ard.2003.015172</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van Leeuwen</surname><given-names>MA</given-names></name><name><surname>van Rijswijk</surname><given-names>MH</given-names></name><name><surname>Sluiter</surname><given-names>WJ</given-names></name><name><surname>van Riel</surname><given-names>PL</given-names></name><name><surname>Kuper</surname><given-names>IH</given-names></name><name><surname>Putte</surname><given-names>LB van de</given-names></name><name><surname>Pepys</surname><given-names>MB</given-names></name><name><surname>Limburg</surname><given-names>PC</given-names></name></person-group><article-title>Individual relationship between progression of radiological damage and the acute phase response in early rheumatoid arthritis. Towards development of a decision support system</article-title><source>J Rheumatol</source><year>1997</year><volume>24</volume><fpage>20</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">9002006</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>&#x000d8;deg&#x000e5;rd</surname><given-names>S</given-names></name><name><surname>Landew&#x000e9;</surname><given-names>R</given-names></name><name><surname>Heijde</surname><given-names> van der</given-names></name><name><surname>Kvien</surname><given-names>TK</given-names></name><name><surname>Mowinckel</surname><given-names>P</given-names></name><name><surname>Uhlig</surname><given-names>T</given-names></name></person-group><article-title>Association of early radiographic damage with impaired physical function in rheumatoid arthritis: a ten-year, longitudinal observational study in 238 patients</article-title><source>Arthritis Rheum</source><year>2006</year><volume>54</volume><fpage>68</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">16385497</pub-id><pub-id pub-id-type="doi">10.1002/art.21548</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Maradit-Kremers</surname><given-names>H</given-names></name><name><surname>Nicola</surname><given-names>PJ</given-names></name><name><surname>Crowson</surname><given-names>CS</given-names></name><name><surname>Ballman</surname><given-names>KV</given-names></name><name><surname>Gabriel</surname><given-names>SE</given-names></name></person-group><article-title>Cardiovascular death in rheumatoid arthritis: a population-based study</article-title><source>Arthritis Rheum</source><year>2005</year><volume>52</volume><fpage>722</fpage><lpage>732</lpage><pub-id pub-id-type="pmid">15751097</pub-id><pub-id pub-id-type="doi">10.1002/art.20878</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Book</surname><given-names>C</given-names></name><name><surname>Saxne</surname><given-names>T</given-names></name><name><surname>Jacobsson</surname><given-names>LT</given-names></name></person-group><article-title>Prediction of mortality in rheumatoid arthritis based on disease activity markers</article-title><source>J Rheumatol</source><year>2005</year><volume>32</volume><fpage>430</fpage><lpage>434</lpage><pub-id pub-id-type="pmid">15742433</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hobbs</surname><given-names>FD</given-names></name><name><surname>Davis</surname><given-names>RC</given-names></name><name><surname>Roalfe</surname><given-names>AK</given-names></name><name><surname>Hare</surname><given-names>R</given-names></name><name><surname>Davies</surname><given-names>MK</given-names></name><name><surname>Kenkre</surname><given-names>JE</given-names></name></person-group><article-title>Reliability of N-terminal pro-brain natriuretic peptide assay in diagnosis of heart failure: cohort study in representative and high risk community populations</article-title><source>BMJ</source><year>2002</year><volume>324</volume><fpage>1498</fpage><pub-id pub-id-type="pmid">12077039</pub-id><pub-id pub-id-type="doi">10.1136/bmj.324.7352.1498</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Galasko</surname><given-names>GI</given-names></name><name><surname>Lahiri</surname><given-names>A</given-names></name><name><surname>Barnes</surname><given-names>SC</given-names></name><name><surname>Collinson</surname><given-names>P</given-names></name><name><surname>Senior</surname><given-names>R</given-names></name></person-group><article-title>What is the normal range for N-terminal pro-brain natriuretic peptide? How well does this normal range screen for cardiovascular disease?</article-title><source>Eur Heart J</source><year>2005</year><volume>26</volume><fpage>2269</fpage><lpage>2276</lpage><pub-id pub-id-type="pmid">16040618</pub-id><pub-id pub-id-type="doi">10.1093/eurheartj/ehi410</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>St Peter</surname><given-names>JV</given-names></name><name><surname>Hartley</surname><given-names>GG</given-names></name><name><surname>Murakami</surname><given-names>MM</given-names></name><name><surname>Apple</surname><given-names>FS</given-names></name></person-group><article-title>B-type natriuretic peptide (BNP) and N-terminal pro-BNP in obese patients without heart failure: relationship to body mass index and gastric bypass surgery</article-title><source>Clin Chem</source><year>2006</year><volume>52</volume><fpage>680</fpage><lpage>685</lpage><pub-id pub-id-type="pmid">16497939</pub-id><pub-id pub-id-type="doi">10.1373/clinchem.2005.062562</pub-id></citation></ref></ref-list></back></article> 